Human Atheromatous Plaque Extracts Induce Tissue Factor Activity (TFa) in Monocytes and also Express Constitutive TFa

Summary

Tissue factor activity (TFa) is a major activator of the coagulation cascade and may play a role in atheroma-induced thrombosis. Mono-cyte-macrophages (MO-MF) generate considerable quantities of TFa when stimulated by a variety of inducers. To test the hypothesis that MO could be induced by atheromatous plaque to generate TFa, plaque extracts obtained from patients with obstructive atheromatous disease were used. These extracts were also assayed for constitutive TFa. The constitutive activity was variable from extract to extract but could be very high, up to 250 U TFa. The TFa induced in MO could be also very high, up to 200 U (i.e. 1/5 of the TFa of full strength rabbit brain thromboplastin). These findings point to a major role for MO-MF TFa in the induction or thrombosis by atheromatous plaque.

 

• References

• 1 Constantinides P. Plaque fissures in human coronary thrombosis. J Atheroscler Res 1966; 6: 1-17.
• 2 Davies MJ, Thomas AC. Plaque fissuring: The cause of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br Heart J 1985; 53: 363-73.
• 3 Fuster V, Badimon L, Badimon JJ, Chesebro JM. The pathogenesis of coronary artery disease and the acute coronary syndromes: Parts l and 2. N Engl J Med 1992; 326: 242-50 3l0-8
• 4 Levin DC, Fallon JT. Significance of the angiographic morphology of localized coronary stenoses: histopathologic correlations. Circulation 1982; 66: 316-20.
• 5 Ross R. Atherosclerosis: A defense mechanism gone awry. Amer J Path 1993; 143: 987-1002.
• 6 Johnson DE, Hinohara T, Selmon MR, Braden LJ, Simpson JB. Primary peripheral arterial stenoses and restenoses excised by transluminal atherectomy: a histopathologic study. J Am Coll Cardiol 1990; 15L: 419-25.
• 7 Schwartz l, Bourassa MG, Lesperance J, Aldridge HE, Kasim F, Salvatori VA, Henderson M, Bonan R, David PR. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988; 318: 1714-9.
• 8 Nemerson Y. Tissue factor and hemostasis. Blood 1988; 71: 1-8.
• 9 Osterud B, Rapaport SI. Activation of Factor IX by the reaction product of tissue factor and Factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260-4.
• 10 Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Head Sci USA 1989; 86: 2839-43.
• 11 Colucci M, Balconi G, Lorenzet R, Pietra A, Locati D, Donati MB, Semeraro N. Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 1983; 71: 1893.
• 12 Marmur JD, Rossikhina M, Guha A, Fyfe B, Friedrich V, Mendlowitz M, Nemerson Y, Taubman MB. Tissue factor is rapidly induced in arterial smooth muscle after balloon injury. J Clin Invest 1993; 91: 2253-9.
• 13 Niemetz J, Fani K. Role of leukocytes in blood coagulation and the generalized Shwartzman reaction. Nature New Biol 1971; 232: 247-8.
• 14 Niemetz J. The coagulant activity of leukocytes: Tissue factor activity. J Clin Invest 1972; 5l: 307-13.
• 15 Rothberger H, Zimmerman TS, Spielgelberg HL, Vaughn JM. Leukocyte procoagulant activity: Enhancement of production in vitro by IgG and antigen-antibody complexes. J Clin Invest 1977; 59: 549-57.
• 16 Muhlfelder T, Niemetz J, Kreutzer Beebe D, Ward PA, Rosenfeld S. C5 chemotactic fragment induces leukocyte production of tissue factor activity-link between complement and coagulation. J Clin Invest 1979; 63: 147-50.
• 17 Levy GA, Schwartz BS, Curtiss LK, Edgington TS. Plasma lipoprotein induction and suppression of the generation of cellular procoagulant activity in vitro: Requirements for cellular collaboration. J Clin Invest 1981; 67: 1614-22.
• 18 Schwartz BS, Levy GA, Curtiss LK, Fair DS, Edgington TS. Plasma lipo-protein induction and suppression of the generation of cellular procoagulant activity in vitro: Two procoagulant activities are produced by peripheral blood mononuclear cells. J Clin Invest 1981; 67: 1650-8.
• 19 Thiagarajan P, Niemetz J. Procoagulant-tissue factor activity of circulating peripheral blood leukocytes. Results of in vivo studies. Thromb Res 1980; 17: 891-6.
• 20 Osterud B, Glaegstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection. Thromb Haemost 1983; 49 (01) 5-7.
• 21 Leatham PM, Bath W, Tooze JA, Camm AJ. Increased monocyte factor expression in coronary disease. Br Heart J 1995; 73: 10-3.
• 22 Tipping PA, Malliaros J, Holdsworth SR. Procoagulant activity expression by macrophages from atheromatous vascular plaques. Atheroscl 1989; 79: 237-43.
• 23 Coller BS, Peerschke EL, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983; 72: 325-38.
• 24 Gold HK, Coller BS, Yasuda T, Saito T, Fallon JT, Guerrero JL, Leinbach RC, Ziskind AA, Collen D. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation 1988; 77: 670-7.
• 25 The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
• 26 Lorenzet R, Niemetz J, Marcus NJ, Broekman MJ. Enhancement of mononuclear procoagulant activity by platelet l2-hydroxyeicosatetraenoic acid. J Clin Invest 1986; 78: 418-23.
• 27 Chmielewska J, Sundin G, Lundell K, Lothgren A, Ericksson B, Risberg B, Andersson LO. Thrombogenicity of human atherosclerotic plaques. Thromb Haemost 1993; 69 (06) 1013 (Abstr.)
• 28 Muhlfelder T, Teodorescu V, Esseesse I, Niemetz J. Procoagulant activity of atheromatous plaques from human arteries. Thromb Haemost 1993; 69 (06) 1176 (Abstr.)
• 29 Jonasson L, Holm J, Skalli O, Boudjers CT, Hansson AV. Regional accumulation of T cell, macrophages and smooth muscle cells in human athero-sclerotic plaque. Arteriosclerosis 1986; 6: 131-8.
• 30 Valente AJ, Rozek MM, Sprague EA, Schwartz CJ. Mechanisms in intimal monocyte-macrophage recruitment. A special role for monocyte chemo-tactic protein-1. Circulation (suppl) 1992; 86: III-20-5.
• 31 Muhlfelder TW, Khan I, Niemetz J. Factors influencing the release of pro-coagulant-tissue factor activity from leukocytes. J Lab Clin Med 1978; 92: 65-72.
• 32 Celi A, Pellegrini G, Lorenzet R, De-Blasi A, Ready N, Furie BC, Furie B. P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci USA 1994; 91 (19) 8767-71.
• 33 Marmur JD, Thiruvikraman SV, Fyfe BS, Guha A, Sharma SK, Ambrose JA, Fallon JT, Nemerson Y, Taubman MB. Identification of active tissue factor in human coronary atheroma. Circulation 1996; 94 (06) 1226-32.
• 34 Thiruvikraman SV, Guha A, Roboz J, Taubman MB, Nemerson Y, Fallon JT. In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X. Laboratory Investigation 1996; 75 (04) 451-61.
• 35 Poon M, Hsu WC, Bogadanov VY, Taubman MB. Secretion of monocyte chemotactic activity by cultured rat aortic smooth muscle cells in response to PDGF is due predominantly to the induction of JE/MCP-1. Am J Path 1996; 149 (01) 307-17.
• 36 Zeiher AM, Fisslthaler B, Schray-Utz B, Busse R. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circulation Research 1995; 76 (06) 980-6.
• 37 van-Zanten GH, de-Graaf S, Slootweg PJ, Heijnen HF, Connolly TM, de-Groot PG, Sixma JJ. Increased platelet deposition on atherosclerotic coronary arteries. J Clin Invest 1994; 93 (02) 615-32.
• 38 Ardissino D, Merlini PA, Ariens R, Coppola R, Bramucci E, Mannucci PM. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. The Lancet 1997; 349: 769-71.